Cargando…

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors

Malignant pleural mesothelioma (MPM) originates in most of the cases from chronic inflammation of the mesothelium due to exposure to asbestos fibers. Given the limited effect of chemotherapy, a big effort is being made to find new treatment options. The PI3K/mTOR pathway was reported to be upregulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Echeverry, N, Ziltener, G, Barbone, D, Weder, W, Stahel, R A, Broaddus, V C, Felley-Bosco, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669703/ https://www.ncbi.nlm.nih.gov/pubmed/25950487 http://dx.doi.org/10.1038/cddis.2015.124

Ejemplares similares

Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models
por: Barbone, Dario, et al.
Publicado: (2015)

GAS5 long non-coding RNA in malignant pleural mesothelioma
por: Renganathan, Arun, et al.
Publicado: (2014)

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2017)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis
por: Thies, Svenja, et al.
Publicado: (2015)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2014)

Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2016)

Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring
por: Cerciello, Ferdinando, et al.
Publicado: (2013)

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2019)

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
por: Oehl, Kathrin, et al.
Publicado: (2018)

Genomic landscape of pleural and peritoneal mesothelioma tumours
por: Hiltbrunner, Stefanie, et al.
Publicado: (2022)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma
por: Sun, Suna, et al.
Publicado: (2022)

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
por: Petrausch, Ulf, et al.
Publicado: (2012)

The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition
por: Felley-Bosco, Emanuela, et al.
Publicado: (2023)

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
por: Bonelli, Mara A., et al.
Publicado: (2017)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
por: Belyanskaya, Larisa L, et al.
Publicado: (2007)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Hedgehog Signaling in Mesothelioma: 2019 Status
por: Felley-Bosco, Emanuela
Publicado: (2019)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
por: Dolly, Saoirse O, et al.
Publicado: (2017)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
por: Zauderer, Marjorie G., et al.
Publicado: (2021)

Autophagy initiation correlates with the autophagic flux in 3D models of mesothelioma and with patient outcome
por: Follo, Carlo, et al.
Publicado: (2016)

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
por: Schröder, Christina, et al.
Publicado: (2019)

Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions
por: Felley-Bosco, Emanuela
Publicado: (2018)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Proposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2022)

Mesothelioma Driver Genes, Ferroptosis, and Therapy
por: Felley-Bosco, Emanuela, et al.
Publicado: (2019)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_magnt7mn2smp5701r382kekq0c